CADL - Candel gains FDA orphan status for brain tumor candidate
2024-05-30 08:50:10 ET
More on Candel Therapeutics
- Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
- Candel Therapeutics GAAP EPS of -$0.28
- Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment
- Seeking Alpha’s Quant Rating on Candel Therapeutics
- Historical earnings data for Candel Therapeutics